Slide 1: Q4 and FY2024 Financial Results and Recent Business Highlights
CytoSorbents Corporation Nasdaq: CTSO Q4 and FY2024 Financial Results and Recent Business Highlights Conference Call March 31, 2025
Slide 2: Conference Call Participants
Conference Call Participants Phillip Chan, MD, PhD Moderator: Adanna Alexander, PhD Chief Executive Officer VP Investor Relations, ICR Healthcare Peter Mariani, CPA Chief Financial Officer 2
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 4: Operational Update
Operational Update Phillip Chan, MD, PhD Chief Executive Officer 4
Slide 5: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology o CytoSorb • Treatment of
Slide 6: 2024: A Strong Year of Progress
2024: A Strong Year of Progress 2024 Product Sales of $35.6M, 15% growth, 71% gross margins, highlighted by 25% growth in Q4 2024 from a year ago. In 2024: 28% growth in Direct Sales outside Germany 22% growth in Distributor/Partner Sales Flat growth in Germany Achieved key regulatory mile
Slide 7: CytoSorb Update
aoa CytoSorb Update CytoSorhents.
Slide 8: CytoSorb Targets Massive Inflammation - the Heart of Critical Illness
CytoSorb Targets Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE S
Slide 9: We Are Expanding the Dimension of Blood Purification
We Are Expanding the Dimension of Blood Purification Sepsis, Septic Shock, Liver Cytokine storm/ Other Shock Cytokine release Pancreatitis failure syndrome Infectious diseases Post-surgical Neuroinflammation (flu, COVID-19, other) Burn injury complications Organ transplant Acute Respiratory High ris
Slide 10: CytoSorb Integrated Approach for Critical Care
CytoSorb Integrated Approach for Critical Care Myoglobin Right Break the Bilirubin Patient Cycle of Deadly Inflammation Free hemoglobin Highest Overdose Chance for Reverse drugs Good Instability Clinical Outcome Digestive enzymes Right Right Timing Dose Restore and Preserve Many Organ Others Functio
Slide 11: Early starters and high intensity pts have significant better survival
Early starters and high intensity pts have significant better survival CATEGORIES EXPECTED MORTALITY (%) OBSERVED MORTALITY (%) All (n=175) Early Starters (n=102) Late Starters (n=73) 70 51 NS High Intensity (n=90) Low Intensity (n=85 Early starters-High Intensity (n=56) m “According Late Starters-L
Slide 12: Restoring Germany to Growth
Restoring Germany to Growth • Germany sales have been flat for two consecutive years • Entering 2025, we initiated a significant reorganization of our direct sales team and strategy in Germany, including a rebalancing of territories and hospital accounts • Goal was to restore sales growth through: •
Slide 13: DrugSorb-ATR Update
13 6 Dru gSorb Update ATR CytoSorhents.
Slide 14: Targets Unmet Need in Blood Thinner Removal
Targets Unmet Need in Blood Thinner Removal With the exception of CytoSorb in the E.U., there are no approved reversal agents for Brilinta in the U.S., E.U., or Canada Heart attack patients are often placed on aspirin and Brilinta (ticagrelor) in the ER to reduce worsening symptoms Most patients wil
Slide 15: DrugSorb-ATR is a Potential Win for All Stakeholders
DrugSorb-ATR is a Potential Win for All Stakeholders Patients Minimize delays to definitive surgery Reduce serious bleeding risk, which is associated with longer hospital stays and increased morbidity and mortality Surgeons No change in workflow, seamless integration into heart-lung machine
Slide 16: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1-2 Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagr
Slide 17: Preparing for Potential Launch
Preparing for Potential Launch • As we wait for FDA and Health Canada decisions, we are preparing for a potential controlled market release that targets our clinical trial centers for several months before a broader national launch • Get real-world feedback • Validate assumptions • Refine our commer
Slide 18: Financial Highlights
Financial Highlights Peter J. Mariani Chief Financial Officer 18
Slide 19: Solid Product Revenue
Solid Product Revenue Performance 4Q24 4Q23 YoY Change Product revenue $9.2m $7.3m +25% Grant income* $1.0m $1.3m -23% Total Revenue Under Historical Convention For Comparative $10.2m $8.6m 17% Purposes only *We have historically reported grant income as a component of total revenue and cost of reve
Slide 20: Return to More Normalized Gross Margin
Return to More Normalized Gross Margin 4Q24 3Q24 4Q23 (as restated) Gross margin 71% 61% 68% 20
Slide 21: Improved Operating Leverage
Improved Operating Leverage 4Q24 4Q23 (as restated) YoY Change Total operating expenses $10.2 m $14.6 m 30% decrease Operating loss $3.7 m $9.6 m 61% improvement Adjusted EBITDA loss $2.4 m $8.1 m 70% improvement Net loss $7.5 m / $0.14/sh $6.1 m / $0.13/sh Adjusted net loss $1.7 m / $0.03/sh $7.5 m
Slide 22: Strengthening Balance Sheet
Strengthening Balance Sheet Cash Management Net cash burn was approximately $2.5 million during the quarter versus approximately $2.7 million in Q3 2024 Strengthened balance sheet with Rights Offering $7.3m, net proceeds raised to date The raise released $5.0m of restricted cash currently on our boo
Slide 23: 2024 Revenue
2024 Revenue 2024 2023 YoY Change Product revenue $35.6m $31.1m +15% Grant income* $3.6m $5.3m -32% Total Revenue Under Historical Convention For Comparative $39.2m $36.4m 8% Purposes only *We have historically reported grant income as a component of total revenue and cost of revenue, as well as a r
Slide 24: Solid 2024 Performance
Solid 2024 Performance Performance Metric 2024 2023 (as restated) YoY Change Product revenue $35.6 m $31.1 m +15% Gross margin 71% 71% Total operating expenses $41.9 m $53.9 m 22% improvement Operating loss $16.7 m $31.9 m 47% improvement Adjusted EBITDA loss $11.5 m $26.2 m 56% improvement Net loss
Slide 25: Closing Remarks
Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer 25
Slide 26: In Memoriam
In Memoriam James E. Cason, Jr. Vice President and Corporate Controller 2014-2025 26
Slide 27: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is an established, international core business in critical care and cardiac surgery with $35M+ in high margin product sales with expectations for growth due to: Significant market opportunity, targeting major unmet medical needs “Right patient at the
Slide 28: Q&A Session
Q&A Session NASDAQ: CTSO Company Contact: Investor Relations Contact: Dr. Phillip Chan Aman Patel & Adanna Alexander pchan@cytosorbents.com ICR Healthcare ir@cytosorbents.com 28